- Home
- VCYT vs DNLI Comparison
VCYT vs DNLI Comparison
Compare VCYT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCYT | DNLI |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VCYT | DNLI |
|---|---|---|
| Price | $38.97 | $21.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $46.50 | $30.80 |
| AVG Volume (30 Days) | 750.6K | ★ 1.6M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.39 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.95 | N/A |
| Revenue Next Year | $11.97 | $3,886.00 |
| P/E Ratio | $111.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.61 | $10.57 |
| 52 Week High | $50.71 | $23.77 |
Technical Indicators
Market Signals| Indicator | VCYT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 59.74 |
| Support Level | $37.98 | $13.29 |
| Resistance Level | $46.24 | $23.77 |
| Average True Range (ATR) | 1.47 | 1.18 |
| MACD | 0.37 | 0.11 |
| Stochastic Oscillator | 84.06 | 76.51 |
Price Performance
Historical ComparisonAbout VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.